Valuation: Haleos Labs Limited

Market Cap 4.32B 45.37M 40.64M 37.49M 33.93M 63.45M 64.47M 447M 178M 2.26B 170M 167M 7.16B P/E 2025
16.2x
P/E 2026 20.9x
Enterprise Value 5.41B 56.86M 50.93M 46.98M 42.52M 79.5M 80.79M 561M 224M 2.83B 213M 209M 8.97B EV / Sales 2025
1.19x
EV / Sales 2026 1.41x
Free-Float
25.03%
Yield 2025
0.14%
Yield 2026 0.13%
1 day-2.78%
1 week-7.28%
Current month-7.46%
1 month-7.46%
3 months-9.79%
6 months-4.63%
Current year+4.94%
1 week 1,389.4
Extreme 1389.4
1,495
1 month 1,389.4
Extreme 1389.4
1,652.7
Current year 1,091.1
Extreme 1091.1
1,774
1 year 1,091.1
Extreme 1091.1
1,774
3 years 487.05
Extreme 487.05
1,774
5 years 472.05
Extreme 472.05
1,774
10 years 128.45
Extreme 128.45
1,774
Manager TitleAgeSince
Chief Executive Officer 66 2017-05-31
Director of Finance/CFO - 2017-05-31
Chief Administrative Officer - 1995-07-06
Director TitleAgeSince
Director/Board Member - 2020-08-20
Chairman 66 -
Director/Board Member 69 2017-05-24
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%-7.28%+19.38%+172.27% 45.37M
+6.63%+5.13%+68.86%+145.20% 1,224B
+1.53%+2.84%+47.48%+89.01% 662B
+1.68%+1.96%+29.16%+109.31% 514B
+0.73%+2.45%+54.26%+68.96% 388B
+3.83%-0.62%+69.01%+42.32% 361B
+2.38%+2.65%+34.31%+57.95% 302B
+2.26%+0.55%+3.92%+28.92% 271B
+1.97%+3.01%+57.91%+76.14% 249B
+4.03%+5.36%+39.76%+116.14% 205B
Average +1.83%+1.20%+42.41%+90.62% 417.69B
Weighted average by Cap. +2.26%+3.04%+50.45%+96.49%

Financials

2025 2026
Net sales 3.45B 36.2M 32.42M 29.91M 27.07M 50.62M 51.44M 357M 142M 1.8B 136M 133M 5.71B 3.34B 35.05M 31.4M 28.97M 26.21M 49.01M 49.81M 346M 138M 1.75B 132M 129M 5.53B
Net income 201M 2.11M 1.89M 1.74M 1.58M 2.95M 3M 20.82M 8.31M 105M 7.92M 7.76M 333M 173M 1.82M 1.63M 1.5M 1.36M 2.54M 2.58M 17.92M 7.15M 90.6M 6.82M 6.68M 287M
Net Debt 859M 9.02M 8.08M 7.45M 6.75M 12.61M 12.82M 88.94M 35.48M 450M 33.86M 33.13M 1.42B 1.09B 11.48M 10.28M 9.49M 8.59M 16.05M 16.31M 113M 45.15M 572M 43.09M 42.17M 1.81B
Projected Income Statement - Annual - Haleos Labs Limited
Logo Haleos Labs Limited
Haleos Labs Limited is an India-based company. The Company is engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with all types of organic & inorganic chemicals, pharmaceuticals, active pharmaceutical ingredients (API) and intermediates. It caters to both domestic and international markets, with its product portfolio comprising established products such as Ranitidine hydrochloride (HCL) and Famotidine, along with other APIs and intermediates. Its products include Ranitidine HCl (Form-2) USP/EP/IP, Famotidine USP/EP/IP, Sildenafil Citrate USP/EP/IP, Allopurinol USP/EP/IP, Ropivacaine HCl USP/EP/IP, Dapsone USP/EP/BP, Sibutramine HCl USP, Itraconazole USP/EP, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP/IP, Tiagabine HCl USP, Albendazole USP/EP/IP, Fosaprepitant Dimeglumine, Hydroxyzine HCl USP/EP/IP, Trazodone HCl USP/EP/IP, and others.
Employees
611
Date Price Change Volume
26-10-30 ₹1,389.40 -2.78% 778
26-10-29 ₹1,429.20 -1.48% 1,100
26-10-28 ₹1,450.60 -1.59% 994
26-10-27 ₹1,474.00 +0.70% 1,594
26-10-26 ₹1,463.70 -2.32% 2,639
  1. Stock Market
  2. Stocks
  3. HALEOSLABS Stock